Research In Polycystic Ovarian Syndrome Today's Era

Dr.T. Nandita[1], Dr. Vinaykumar Hiremath[2], Dr. Rakeshgouda. N. Bhagvantgoudra[3]
[1]*PhD Scholar Department of Rachana shareera SDM College of Ayurveda Kuthpadyudupi, Karnataka, India*
[2]*ProfessorDept. of Ayurveda Samhita and Siddhanta Ayurveda Mahavidialaya, Hubli, Karnataka*, India
[3]*PG Scholar Dept of Rachana Shareera Ayurveda Mahavidialaya, Hubli, Karnataka, India*

Abstract- Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting individuals with ovaries, primarily during their reproductive years. It is characterized by a combination of symptoms, including irregular menstrual cycles, anovulation (lack of ovulation), hyperandrogenism (elevated levels of male hormones, leading to symptoms like hirsutism and acne), and the presence of multiple cysts in the ovaries. The exact cause of PCOS is unknown, but it is thought to involve a combination of genetic, hormonal, and environmental factors. Insulin resistance is also frequently associated with PCOS, increasing the risk of developing type 2 diabetes and metabolic syndrome. Diagnosis typically involves a combination of clinical evaluation, laboratory tests to assess hormone levels, and ultrasound imaging to identify cysts in the ovaries. Management of PCOS focuses on symptom control and may include lifestyle changes, medications to regulate menstrual cycles, address insulin resistance, and treat symptoms of hyperandrogenism. Long-term management aims to reduce the risk of complications such as infertility, diabetes, and cardiovascular disease.

Objective- The objective for managing Polycystic Ovary Disease (PCOD) or Polycystic Ovary Syndrome (PCOS) primarily focuses on addressing the diverse symptoms and reducing the long-term health risks associated with the condition. The main goals include:

1. **Restoring Hormonal Balance:**
   - **To regulate menstrual cycles and restore normal ovulation, which can help address irregular periods and infertility.**
2. **Managing Hyperandrogenism:**
   - **To reduce symptoms related to excess male hormones (androgens), such as hirsutism (excessive hair growth), acne, and male-pattern baldness.**
3. **Improving Fertility:**
   - **To enhance the chances of conception for women who are trying to conceive, through medical treatments like ovulation induction or assisted reproductive technologies (e.g., IVF).**
4. **Addressing Metabolic Issues:**
   - **To improve insulin sensitivity and prevent or manage metabolic disorders such as obesity, insulin resistance, and type 2 diabetes.**
5. **Preventing Long-term Health Complications:**
   - **To reduce the risk of cardiovascular diseases, type 2 diabetes, and endometrial cancer associated with PCOS.**
6. **Improving Quality of Life:**
   - **To alleviate the psychological impact of PCOS, such as anxiety, depression, and body image issues, by addressing both the physical and emotional challenges faced by affected individuals.**
7. **Weight Management:**
   - **To promote weight loss or management through lifestyle modifications, including diet and exercise, as this has a significant impact on regulating menstrual cycles and improving metabolic health.**

These objectives guide the holistic treatment approach for managing PCOS, aiming for symptom relief, fertility support, and long-term health maintenance.

Keywords- PCOS, Ovarian Dysfunction, Hyperandrogenism, Irregular Menstrual Cycles, Anovulation, Polycystic Ovaries, Ovulation Induction

INTRODUCTION

The polycystic ovary syndrome (PCOS) is a hyperandrogenic disorder associated with chronic oligo-anovulation and polycystic ovarian morphology[1]. It is characterized by hormonal imbalances that disrupt the normal functioning of the ovaries, leading to a variety of symptoms. PCOS is one of the leading causes of infertility due to irregular or absent ovulation. Individuals with PCOS may experience a range of symptoms, including irregular menstrual cycles, excess hair growth (hirsutism), acne, and weight gain. The condition is also associated with

metabolic abnormalities such as insulin resistance, increased risk of type 2 diabetes, and cardiovascular diseases.

The exact cause of PCOS is still not fully understood, but it is believed to involve a combination of genetic and environmental factors. Insulin resistance and excess androgen production are key factors contributing to the development of the condition. In addition to its physical symptoms, PCOS can have psychological effects, leading to issues such as anxiety, depression, and poor body image due to visible symptoms like acne and excessive hair growth. Although there is no cure for PCOS, its symptoms can be managed through lifestyle changes, medications, and fertility treatments. Early diagnosis and intervention are critical in managing the symptoms and reducing the risk of long-term complications. As awareness of PCOS continues to grow, efforts to better understand its underlying mechanisms and improve treatment options remain ongoing.

Steroidogenesis in PCOS:

In normal women, androgen production rate (PR) is the result of adrenal and ovarian secretion and conversion from precursors in peripheral tissues, particularly the adipose tissue and skin[2]. Steroidogenesis refers to the process by which steroids (such as estrogen, progesterone, cortisol, and androgens) are produced in the body. In Polycystic Ovary Syndrome (PCOS), steroidogenesis is often disrupted, leading to hormonal imbalances that contribute to the condition's characteristic symptoms, such as irregular menstrual cycles, infertility, and signs of hyperandrogenism (excessive male hormones, particularly testosterone).

Steroidogenesis in PCOS is marked by an imbalance in the production of androgens and estrogens, driven by elevated LH levels, insulin resistance, and impaired follicular development. This hormonal disruption leads to the clinical manifestations of PCOS, including irregular cycles, infertility, and signs of hyperandrogenism such as hirsutism and acne. Managing these hormonal imbalances is key to treating the condition, often through medications that reduce androgens (like anti-androgens), regulate insulin sensitivity (such as metformin), or induce ovulation (like clomiphene citrate).

Androgen Production in PCOS:

Androgens are male sex hormones, but they are also present in smaller amounts in females. In Polycystic Ovary Syndrome (PCOS), androgen production is often elevated, leading to many of the common symptoms associated with the condition. The primary androgens involved are testosterone, androstenedione, and Dehydroepiandrosterone sulfate as well as that of androstenediol and 11β-hydroxy androstenedione [3].

Androgen overproduction is a central feature of PCOS and contributes to many of the disorder's clinical manifestations, including hirsutism, acne, alopecia, and menstrual irregularities. The increased androgen levels in PCOS are primarily due to excessive ovarian production stimulated by elevated LH and insulin resistance. Management typically involves medications to regulate hormone levels, improve insulin sensitivity, and reduce the impact of androgens on the body. Understanding and addressing androgen excess is essential for treating the symptoms and long-term health risks associated with PCOS. Compared with healthy subjects, women with previous PCOS have an increased adrenal capacity to secrete androgens that remains until after menopause. These results confirm the adrenals contribute significantly to hyperandrogenism in PCOS and similarly to ovarian androgen secretion capacity, women with PCOS exhibit enhanced adrenal androgen production until their late reproductive years[4]

Sympathetic nerve activity and hyperandrogenism

Many factors associated with polycystic ovary syndrome (PCOS) are also associated with increased activity in the sympathetic nervous system[5]. Increased ovarian sympathetic nerve activity might contribute to PCOS by stimulating androgen secretion[6]. Nerve growth factor (NGF) is a strong marker for sympathetic nerve activity and recently it was demonstrated that women with PCOS has enhanced ovarian NGF production[7]. Polycystic ovary syndrome (PCOS) is a complex condition that affects hormone levels, metabolism, and the reproductive system. It is commonly associated with elevated androgen levels (hyperandrogenism), which can cause symptoms like

acne, hirsutism (excessive hair growth), and scalp hair thinning. Interestingly, sympathetic nerve activity (SNA), which regulates the fight-or-flight response and influences various physiological processes, has also been shown to play a role in PCOS.

The relationship between sympathetic nerve activity and hyperandrogenism in PCOS is complex. Increased sympathetic activity can contribute to metabolic disturbances, including insulin resistance, and may directly stimulate androgen production by the ovaries and adrenal glands. This can lead to worsening of hyperandrogenism and its associated symptoms. Addressing both sympathetic activity and hormonal imbalances may help to manage the symptoms and long-term health risks associated with PCOS. Recently, for the first time it was demonstrated that women with PCOS have high general activity in the sympathetic nervous system which may be relevant to the pathophysiology of the syndrome[8].

Mechanism of follicle arrest

The finding that granulosa cells from anovulatory polycystic ovaries responded well to FSH in culture directed initial investigations into follicular arrest towards discovery of raised levels of a locally produced inhibitor. It is difficult to deduce cause and effect, however if the factor is causing follicular arrest, or did the follicular arrest elicit the production of the inhibitor. Androgens are an obvious candidate, but production is raised in theca from ovulatory PCO also[9]. Recent data indicated that it is those women in whom AMH levels fall who have the best response to methods to induce ovulation. Interestingly, the incubation of cells with metformin inhibited AMH production suggesting that this may be one mechanism of the action of this drug in PCOS[10].

Intra-ovarian regulation of ovarian morphology

Kit ligand (KL) is an intra-ovarian cytokine that promotes multiple aspects of folliculogenesis in animal models including primordial follicle activation, follicle growth and survival, stromal cell differentiation, and theca cell proliferation and androgen biosynthesis [11]. Perturbation of these biological processes occur in PCO, particularly in anovulatory women with PCOS, in whom there is evidence for abnormal oocyte growth, increased follicle and stromal density, thecal hypertrophy, and increased thecal cell androgen biosynthesis. Therefore, KL may play a key role in the morphogenesis of PCO, particularly in women with PCOS. Androgen regulation of KL has been reported [12], but the role of KL signalling, its regulation in human ovaries and its relevance to PCOS are currently unknown.

Hyperthecosis

In PCOS (Polycystic Ovary Syndrome) refers to a more severe form of ovarian dysfunction, where the ovaries exhibit excessive production of androgens (male hormones like testosterone). It is a condition that typically involves the theca cells of the ovaries, which are responsible for androgen production. Hyperinsulinemia is also frequently part of the phenotype [13]. Hyperthecosis in PCOS represents a more severe form of androgen excess, often characterized by significantly elevated androgen levels and more pronounced symptoms like hirsutism, scalp hair thinning, and acne. It is typically associated with increased ovarian androgen production due to theca cell hyperplasia and heightened responsiveness to LH.

Dyslipidemia in PCOS

In PCOS (Polycystic Ovary Syndrome) refers to an abnormality in lipid levels, which is a common metabolic issue in women with PCOS. This can involve elevated levels of total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol (often referred to as "bad" cholesterol), and/or decreased levels of high-density lipoprotein (HDL) cholesterol (the "good" cholesterol). These lipid abnormalities increase the risk of cardiovascular disease and other metabolic disorders in women with PCOS. PCOS is frequently associated with various patterns of dyslipidemia including low highdensity lipoprotein cholesterol (HDL-C), high levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) [14].

PCOS: Inflammation and infection

Growing evidence supports the concept that PCOS is associated with increased oxidative stress and systemic inflammation. When compared to healthy control subjects, women with PCOS have increased markers of lipid peroxidation, elevated levels of c - reactive protein, inflammatory cytokines, ovarian

dysfunction and other alterations characteristic of PCOS. In support of this concept, there is evidence that PCOS is associated with greater risk of exposure to intracellular pathogens capable of inducing long-term inflammation including Chlamydia pneumonia and Chlamydia trachomatis[15]. A correlation between Chlamydia pneumonia and insulin resistance has also been observed. Furthermore, Chlamydia pneumonia infection in mice resulted in increased ovarian size and a greater number of antral follicles.

Vascular disease in women with PCOS

Polycystic Ovary Syndrome is a significant concern, as the condition is linked to several factors that can increase the risk of cardiovascular problems. These include insulin resistance, dyslipidemia (abnormal lipid profiles), obesity, and inflammation, all of which can contribute to the development of atherosclerosis (hardening or narrowing of the arteries) and other vascular issues. Understanding how PCOS affects vascular health is crucial for identifying and managing these risks. The higher sex-specific coronary mortality observed in women compared with men, combined with a greater proportion of women in the population, has resulted in relatively more women dying of cardiovascular disease (CVD) each year than men[16].

SUMMARY

Polycystic Ovary Syndrome (PCOS) is a common hormonal disorder affecting women of reproductive age. It involves a variety of symptoms related to irregular menstrual cycles, elevated androgen levels, and ovarian cysts. The exact cause is not fully understood, but it's thought to result from a combination of genetic and environmental factors, with insulin resistance and inflammation playing key roles. PCOS is a complex, multifactorial condition that involves hormonal imbalance, insulin resistance, and metabolic disturbances. It presents with a variety of symptoms, including irregular periods, excessive hair growth, acne, and infertility. While there is no cure, lifestyle changes and medications can effectively manage symptoms, improve fertility, and reduce the risk of long-term complications such as cardiovascular disease and type 2 diabetes. Early diagnosis and intervention are key to managing PCOS effectively.

REFERENCE

[1] Azziz R, Carmina E, Dewailly, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. Journal of Clinical Endocrinology & Metabolism. 2006; 91:4237–4245. [PubMed: 16940456]

[2] Longcope C. Adrenal and gonadal androgen secretion in normal females. Clinical Endocrinology & Metabolism. 1986; 15:213–228

[3] Piltonen T, Koivunen R, Morin-Papunen L, et al. Ovarian and adrenal steroid production: regulatory role of LH/HCG. Human Reproduction. 2002; 17:620–624. [PubMed: 11870113]

[4] . Puurunen J, Piltonen T, Jaakkola P, et al. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2009; 94:1973–1978. [PubMed: 19318449]

[5] Fagius J. Sympathetic nerve activity in metabolic control--some basic concepts. Acta Physiologica Scandinavica. 2003; 177:337–343. [PubMed: 12609004]

[6] Dissen GA, Lara HE, Leyton V, et al. Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat. Endocrinology. 2000; 141:1073–1082. [PubMed: 10698183]

[7] Dissen GA, Garcia-Ruda C, Paredes A, et al. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology. 2009; 150:2906–2914. [PubMed: 19264868]

[8] Sverrisdottir YB, Mogren T, Kataoka J, et al. Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? American Journal of Physiology Endocrinology and Metabolism. 2008; 294:E576–581. [PubMed: 18198350]

[9] Gilling-Smith C, Story H, Rogers V, et al. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clinical Endocrinology (Oxford). 1997; 47:93–99. [PubMed: 9302378]

[10] Rice S, Pellatt L, Ramanathan K, et al. Metformin inhibits aromatase via an extracellular signalregulated kinase-mediated pathway. Endocrinology. 2009; 150:4794–4801. [PubMed: 19574398]

[11] Driancourt MA, Reynaud K, Cortvrindt R, et al. Roles of KIT and KIT LIGAND in ovarian function. Reviews in Reproduction. 2000; 5:143–152.

[12] Shiina H, Matsumoto T, Sato T, et al. Premature ovarian failure in androgen receptor-deficient mice. Proceeding of the National Academy of Science U S A. 2006; 103:224–229.

[13] Nagamani M, Hannigan EV, Dinh TV, et al. Jul) Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. Journal of Clinical Endocrinology & Metabolism. 1988; 67:144–148. [PubMed: 3288650]

[14] Wild RA, Painter PC, Coulson PB, et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1985; 61:946–951. [PubMed: 4044782]

[15] Morin-Papunen LC, Duleba AJ, Bloigu A, et al. Chlamydia antibodies and self-reported symptoms of oligoamenorrhea and hirsutism: A new etiologic factor in polycystic ovary syndrome? Fertility & Sterility. 2009 [Epub ahead of print].

[16] Thorn T, Haase N, Rosamond W, et al. AHA Statistical Update. Heart disease and stroke statistics update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113:e85–e151. [PubMed: 16407573]